Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Metabolyz vs Nucific

Metabolyz
Graded #339

Higher grade

vs+3.3999999999999986
Nucific
Graded #417

Lower grade

The verdict

Metabolyz takes it — 59.6/100 to 56.2/100.

Metabolyz grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Metabolyz is a nationwide GLP-1 telehealth platform offering three compounded programs — standard semaglutide, dual-agonist tirzepatide, and a microdose protocol for patients near goal weight or intolerant…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
45
45
Dose & formulationNucific +13
40
53
Clinical oversightMetabolyz +5
81
76
Labs & monitoringMetabolyz +11
63
52
FulfillmentMetabolyz +19
86
67
Contract termsMetabolyz +14
55
41
Metabolyz · left barNucific · right bar

The numbers

MetricMetabolyzNucific
WeighScore59.6/10056.2/100
GradeCC
Scorecard rank#339#417
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Metabolyz

Graded #339 · C

Strengths

  • Three GLP-1 programs: standard semaglutide, dual-agonist tirzepatide, and a microdose protocol for near-goal or dose-sensitive patients
  • Nutrition, movement, and lifestyle coaching included in all programs at no extra charge
  • Medication compounded in licensed 503A/503B US pharmacies with temperature-controlled, unmarked direct-to-door delivery
  • Licensed provider supervision with direct messaging access and structured check-ins throughout
  • Telehealth across all 50 states; BMI 27+ eligibility (25+ with weight-related condition)

Where it loses points

  • Pricing is fully gated — not disclosed until after consultation, preventing upfront cost comparison
  • Compounded GLP-1 only — no brand-name options (Wegovy, Zepbound) available
  • No LegitScript certification or named medical leadership found on public-facing pages
  • Labs not mentioned as included — unclear whether baseline or follow-up bloodwork is offered
  • Newer brand with no external reviews, published outcomes data, or notable accreditations
Nucific

Graded #417 · C

Strengths

  • Founder is named and credentialed: Dr. Amy Lee, MD, triple board-certified in Internal Medicine, Obesity Medicine and Clinical Nutrition
  • Cites SURMOUNT-1 properly, naming the trial, the 20.9% average and the Jastreboff NEJM 2022 source
  • Discloses that featured patients were compensated for their time
  • Labels its NAD+ decline chart as illustrative and not a measurement, with an unusually careful methodology note
  • Offers compounded, microdosed and brand-name Ozempic and Zepbound in one catalogue

Where it loses points

  • No price is published anywhere; every option is gated behind a three-minute quiz
  • The LegitScript badge is a self-hosted image with generic alt text rather than the issued embed, so the certification could not be verified
  • A BBB Accredited A+ claim is displayed without a link to the BBB profile
  • No state list and no named pharmacy, only licensed U.S. pharmacies
  • Before-and-after photographs are used alongside compensated testimonials

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard